Evogen
Founded Year
2001Stage
Unattributed | AliveTotal Raised
$6.39MLast Raised
$850K | 9 yrs agoAbout Evogen
This company, formerly known as Sceptor, is a global diagnostics, biological collection and detection systems company dedicated to improving the quality of life and world safety by meeting the needs of multiple markets, including research, clinical, environmental and biodefense diagnostics.
Missing: Evogen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Evogen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Evogen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Evogen is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Evogen Patents
Evogen has filed 6 patents.
The 3 most popular patent topics include:
- Neurological disorders
- Psychiatric diagnosis
- Syndromes
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/4/2020 | 3/7/2023 | Epilepsy, Neurological disorders, Syndromes, Rare diseases, Seizure types | Grant |
Application Date | 6/4/2020 |
|---|---|
Grant Date | 3/7/2023 |
Title | |
Related Topics | Epilepsy, Neurological disorders, Syndromes, Rare diseases, Seizure types |
Status | Grant |
Latest Evogen News
Apr 6, 2022
Dr. SSV Ramakumar of IndianOil, Dr. Kaustav Sinha of Chevron Oronite, Steve Puckett of TRI-ZEN and Lubrizol’s Evogen 4006 to be recognised for industry contributions during F+L Week 2022 in Bangkok, Thailand April 06, 2022 05:33 AM Eastern Daylight Time HONG KONG--( BUSINESS WIRE )--The F&L Asia Awards showcase and celebrate the outstanding contributions and exceptional performance of those working in the fuels and lubricants industry in Asia. After a brief hiatus in 2020 and 2021, due to the impacts of Covid-19, we are excited to confirm the return of these prestigious honours and to announce the award winners for 2022. Recipients will be acknowledged at the F&L Asia Awards Dinner on 28 April at the Siam Anantara Bangkok, during the F+L Week Live! event in Bangkok, Thailand. Dr. Ramakumar is director, R&D and planning & business development, on the Board of Indian Oil Corporation Ltd. (IndianOil), a Fortune 500 company. He has a long and celebrated career at IndianOil with more than three decades of uninterrupted experience in the downstream hydrocarbons sector, notably in the areas of lubricant technology, refinery process research and catalyst development. The “F&L Asia Person of the Year” recognises an individual's outstanding contribution to the fuels and lubricants industry in Asia, whether from the oil, additives, automotive, or other stakeholder industry. Dr. Ramakumar has been instrumental in the development of India’s home-grown, OEM-approved marine lubricant technology, which catapulted IndianOil’s SERVO lubricants into the select league of five MNCs, and has spearheaded the complete indigenisation of IndianOil’s flagship INDMAX refining technology. Dr. Ramakumar was chosen for this prominent industry award for his pioneering work in alternative energy programmes including waste-to-energy, bio, solar and energy storage. He is steering the IndianOil hydrogen endeavours and is on several committees working on defining the strategies for the inclusion of hydrogen in the energy mix. The “F&L Asia Future Leaders Award” for 2022 goes to Dr. Kaustav Sinha. This award recognises our industry’s emerging leaders, with nominees including individuals with up to 15 years of industry experience. Kaustav graduated from the University of Pune in Maharashtra, India in 2002 with a Bachelor of Engineering degree in Instrumentation and Control Engineering. He then obtained his PhD in Materials Science and Engineering from the University of Nevada, Reno in 2008. In 2019, he obtained an MBA from The University of Chicago Booth School of Business. Kaustav is currently manager, global strategic account, and is responsible for managing people, P&L, strategy, business development and operations of one of Chevron Oronite’s largest customer portfolios. Before this, he was leading Chevron Oronite’s North American sales portfolio where he played a vital role in growing the regional business and developed a growth portfolio with a multi-million-dollar opportunity pipeline. Kaustav has actively participated in several industry advocacy positions where he worked closely with industry groups, energy companies and OEMs to develop new specifications and build strategic partnerships. His work in smart materials, automotive tribology and lubricants was extensively presented at 40+ leading conferences and published in over 20 journal articles, proprietary technical reports, and patent applications. A strong advocate of women and minorities, Kaustav volunteers in science, technology, engineering, and business events that support their cause. He is on Chevron’s founding enterprise leadership team of Elevate, an in-house diversity and inclusive program, and regularly engages in diversity, inclusion and mentoring initiatives. Steve Puckett, OBE, is a business leader and independent director with extensive experience in growing businesses in Asia. Over the past 40 years, Steve has forged an impressive career in the energy industry. Originally with ExxonMobil, he held senior executive positions in Asia including in Japan, Hong Kong, China and Singapore. For the past 22 years, Steve has been consulting to clients that have included major international and national oil companies, blue-chip financial institutions, global professional services organisations and government authorities. He is executive chairman of TRI-ZEN International Pte Ltd, an advisory business with a primary focus on strategy, business development, and M&A for the energy industries in Asia. We are excited to be able to recognise Steve’s long-term commitment to the industry with the 2022 “F&L Asia Lifetime Achievement Award”. Steve is the recognised expert on the wider Asia business environment, having developed numerous businesses and projects across the region, ranging from billion-dollar country entries for international corporates to entrepreneurial start-ups. Steve is also the co-founding director of the Asian Lubricants Industry Association (ALIA), the industry body representing Asia’s lubricants value chain, and has been instrumental in enabling ALIA to withstand the challenges presented by Covid-19 at a time when most member companies were focused on their survival. Steve was instrumental in drafting the ALIA Sustainability Statement and in influencing the ALIA Council to make sustainability a key focus for the fledgling organisation. The “F&L Asia Product Development of the Year” award recognises innovation in the fuels and lubricants industry, in particular, products that have made significant improvements to processes, efficiency and ecological use. We are pleased to announce that the 2022 recipient is Evogen 4006 from the Lubrizol Corporation. The global passenger vehicle market has seen a rapid increase in the number of electric and hybrid electric vehicles, however, existing lubricants are not optimised to provide the efficiency and requisite protection of e-devices. Lubrizol launched the Evogen 4001 additive technology in 2019 to address the tougher e-environment. At the time of commercialisation, the product was the first dedicated e-axle fluid available around the world. Original equipment manufacturers have their own unique electric motor design, thus requiring a specific lubricant for their electric motors to fit their needs for better performance. Thus, in 2020, Lubrizol developed Evogen 4006 for a Chinese OEM using a wet electric motor. Evogen 4006 improves copper corrosion protection and enhances electric properties while maintaining excellent gear/bearing protection compared to conventional manual transmission fluids (MTF). Lubrizol has carefully balanced the anti-wear and extreme pressure chemistry to achieve an ideal equilibrium of load carrying, copper corrosion protection and electrical conductivity. These have been rigorously evaluated in conventional lubricant tests as well as new tests better suited to the new environment, such as the copper wire corrosion test. The additive package also offers improved oxidative stability and potential for efficiency gains by enabling durability at low viscosity. Lubrizol also anticipates a 39.2% reduction in carbon dioxide emissions compared with conventional MTFs. F+L Week 2022 will be held from April 27-29 at the Siam Anantara Bangkok in Thailand. Virtual registration (live streaming and on-demand) is also available through our powerful networking platform, which will be launched on April 15. To view the F+L Week 2022 event schedule, click here . F+L Week 2022 is now a hybrid event, so you can attend the event physically or virtually. To register for this event or to attend the F&L Asia Awards Dinner only, click here . The event includes two training workshops, one on electric vehicle fluids and another on sustainable metalworking fluids. To register for the training workshops, either live or virtual, click here . For inquiries, please contact us at conference@fuelsandlubes.com . ABOUT F+L WEEK F+L Week, the annual event for the fuels and lubricants industry, has become an institution since its founding in 1995. F+L Week 2022 will return in April and it will be co-located with the ALIA Annual Meeting. F+L Week will be held from April 27-29, 2022 at the fabulous Siam Anantara Bangkok, the former Four Seasons Bangkok. The conference theme is "Disruption & Transformation in the Fuels & Lubes Industry." We all know the strong synergy between fuels and lubricants. F+L Week 2022 will provide insight into the technical challenges and opportunities that come with these synergies, as well as future technology and market developments. The F+L Week 2022 Conference & Exhibition starts on April 27 with a dedicated networking day for customers and suppliers to connect over coffee, tea, lunch and evening cocktails. Participants can pre-book their appointments via our powerful digital app. In addition, Thailand further loosened its entry requirements on March 1. Click to view Thailand's latest Test and Go program. Contacts
Evogen Frequently Asked Questions (FAQ)
When was Evogen founded?
Evogen was founded in 2001.
Where is Evogen's headquarters?
Evogen's headquarters is located at 10513 W. 84th Terrace, Lenexa.
What is Evogen's latest funding round?
Evogen's latest funding round is Unattributed.
How much did Evogen raise?
Evogen raised a total of $6.39M.
Who are the investors of Evogen?
Investors of Evogen include L Capital Partners, MRIGlobal, MRI Ventures and Shalom Management.
Who are Evogen's competitors?
Competitors of Evogen include MolecularMD, Amnis Corporation, ZyGEM, ProteinSimple, Axela Biosensors and 13 more.
Compare Evogen to Competitors
PrimaDiag is a start-up developing tools to automate biological processes for diagnostics and research
SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.
Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.
Intelligent Medical Devices, dba IntelligentMDx, develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical molecular diagnostics, drug development and applied science applications. Its aim is to translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to improve patient care.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.